Article

A20 is a negative regulator of BCL10- and CARMA3-mediated activation of NF-kappaB.

Dip. Scienze Biologiche ed Ambientali, Università degli Studi del Sannio di Benevento, Via Port'Arsa 11, 82100 Benevento, Italy.
Journal of Cell Science (Impact Factor: 5.33). 05/2008; 121(Pt 8):1165-71. DOI: 10.1242/jcs.021105
Source: PubMed

ABSTRACT The molecular complex containing CARMA proteins, BCL10 and TRAF6 has been identified recently as a key component in the signal transduction pathways that regulate activation of the nuclear factor kappaB (NF-kappaB) transcription factor. Here, we report that the inducible protein A20 negatively regulates these signaling cascades by means of its deubiquitylation activity. We show that A20 perturbs assembly of the complex containing CARMA3, BCL10 and IKKgamma/NEMO, thereby suppressing activation of NF-kappaB. Together, our results further define the molecular mechanisms that control activation of NF-kappaB and reveal a function for A20 in the regulation of CARMA and BCL10 activity in lymphoid and non-lymphoid cells.

0 Bookmarks
 · 
83 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The molecular complexes containing BCL10, MALT1 and CARMA proteins (CBM complex) have been recently identified as a key component in the signal transduction pathways that regulate activation of Nuclear Factor kappaB (NF-κB) transcription factor. Herein we identified the DEP domain-containing protein DEPDC7 as cellular binding partners of CARMA2 and CARMA3 proteins. DEPDC7 displays a cytosolic distribution and its expression induces NF-κB activation. Conversely, shRNA-mediated abrogation of DEPDC7 results in impaired NF-κB activation following G protein-coupled receptors stimulation, or stimuli that require CARMA2 and CARMA3, but not CARMA1. Thus, this study identifies DEPDC7 as a CARMA interacting molecule, and provides evidence that DEPDC7 may be required to specifically convey on the CBM complex signals coming from activated G protein-coupled receptors.
    PLoS ONE 01/2014; 9(12):e116062. · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: •Fifteen years ago, in 1999, BCL10 was cloned as a result of a translocation recurrent in a subset of B cell MALT lymphomas.•In a few years, BCL10 would become one of the key molecules in antigen receptor signaling pathways.•The exact biological function of BCL10 is still not completely elucidated.
    Immunology letters 02/2014; · 2.91 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Initially identified by their ability to modulate the functional activity of BCL10, the three CARMA proteins, CARMA1, -2 and -3, have recently themselves taken a leading role on the stage of molecular medicine. Although considered for some time as simple ancillary proteins, increasingly accumulating recent data evidently indicate a role of primary importance for these three proteins in the pathophysiology of several human tumors and inflammatory disorders. In fact, recent scientific literature clearly establishes that CARMA1 is one of the most mutated genes in a subtype of B-cell lymphoma and, at the same time, responsible for some rare human immunodeficiency conditions. On the other hand, mutations in CARMA2 are responsible for the hereditary transmission of some inflammatory disorders of the skin, including familial psoriasis and ptiriasis; whereas expression of CARMA3 appears to be deregulated in different human tumors. Here we describe and summarize the mutations found in the genes coding for the three CARMA proteins in these different human pathological conditions, and offer an interpretation of the molecular mechanisms from which arise the biological outcomes in which these proteins are involved. J. Cell. Physiol. © 2013 Wiley Periodicals, Inc.
    Journal of Cellular Physiology 12/2013; · 3.87 Impact Factor

Full-text (2 Sources)

Download
45 Downloads
Available from
May 23, 2014